Published in partnership with the

Logo

Club Jules Gonin

Intravitreal ranibizumab for choroidal neovascularization related to traumatic Bruch’s membrane rupture

Feng Liang, Nathalie Puche, Gisèle Soubrane and Eric H. Souied

View Related Documents

Abstract

Purpose  

Choroidal neovascularization (CNV) secondary to traumatic rupture of Bruch’s membrane is a rare condition, without standardized treatment. Here we describe one case of CNV related to traumatic rupture of Bruch’s membrane which was successfully treated with intravitreal injection of ranibizumab.

Methods  

A 14-year-old patient was referred for ocular contusion, complicating interpapillomacular rupture of Bruch’s membrane in left eye. Indeed, a correct initial visual acuity, juxtafoveolar CNV appeared 4 months later on the border of Bruch’s membrane rupture. The patient was treated with an off-label intravitreal ranibizumab because of worsening of visual acuity.

Results  

One month after intravitreal injection, visual acuity improved, from 20/40 to 20/25. At 12-month follow-up, visual acuity remained at 20/25, fundus examination. Fluorescein angiography, indocyanine green angiography and optic coherence tomography showed fibrotic evolution of CNV. The Bruch’s membrane rupture remained stable. No side-effect of intravitreal injection of ranibizumab was observed.

Conclusion  

For this patient affected with CNV secondary to traumatic Bruch’s membrane, one single intravitreal ranibizumab injection was efficient, with 1-year follow-up.

Keywords  Intravitreal ranibizumab - Lucentis - Bruch’s membrane rupture - Choroidal neovascularization

The authors have no proprietary interest in the materials used in this study.

Fulltext Preview

Image of the first page of the fulltext document